
    
      This is open-label, long-term prospective study in a cohort of Fontan subjects taking drug
      daily for one year. The study will determine the scope of hepatic stiffness in the cohort by
      ultrasound and magnetic resonance imaging elastography and evaluate MZ101 pharmacotherapy as
      a potentially efficacious treatment to reduce liver stiffness.
    
  